Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Li, Suoyuan; Yang, Qing; Wang, Hongsheng; Wang, Zhuoying; Zuo, Dongqing; Cai, Zhengdong; Hua, Yaping

doi:10.3892/mco.2016.1066

Cited by 34 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The guidelines recommend measuring LDH level as a tumor marker since it usually correlates with tumor burden and has a prognostic value in ES/PNET [9,10]. Also, a meta-analysis indicated that patients with high serum levels of LDH have a poor prognosis compared to patients with normal serum LDH values [20]. Previous studies showed that tumor size of 8 cm or more is associated with poor survival [3,21].…”

Section: Discussionmentioning

confidence: 99%

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Inagaki

Shimoi²,

Okuma³

et al. 2019

Med Oncol

View full text Add to dashboard Cite

Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/PNET) is an aggressive bone tumor. Bone marrow aspiration and biopsy (BMAB) has been recognized as the gold standard for assessing bone marrow status. While the latest guideline suggests the need to omit bone marrow aspiration in patients with no findings on 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) based on one retrospective report, there is no study using 18 F-FDG PET/computed tomography (CT). We retrospectively reviewed 26 consecutive, previously untreated, ES/PNET patients. We compare the results of bone marrow aspiration and biopsy (BMAB) and those of 18 F-FDG PET/CT in ES/PNET patients. All of the 21 patients without metastases on 18 F-FDG PET/CT had negative BMAB. The sensitivity of bone marrow involvement in bone metastases positive patients on 18 F-FDG PET/CT was 75% (3/4), and the specificity was 100% (22/22). In addition to the metastatic findings on 18 F-FDG PET/CT, tumor diameter, lactate dehydrogenase level at diagnosis, and the presence or absence of bone metastasis were factors related to bone marrow involvement. It may be a reasonable option to omit BMAB in ES/PNET patients with no distant metastasis based on 18 F-FDG PET/CT findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Inagaki

Shimoi²,

Okuma³

et al. 2019

Med Oncol

View full text Add to dashboard Cite

show abstract

“…An elevated serum lactate dehydrogenase (LDH) reflects tumor burden, and Li et al revealed in a meta-analysis that higher levels of LDH are associated with a poorer overall survival and disease-free survival at five years. 12 The classic radiographic appearance of Ewing's sarcoma typically involves a poorly defined, permeative, and destructive intramedullary lesion with onion-skin appearing periosteal elevation and an associated soft-tissue mass. 10 ►Fig.…”

Section: Ewing's Sarcomamentioning

confidence: 99%

Malignant Bone Tumors of the Knee: How to Identify and Treat

et al. 2018

View full text Add to dashboard Cite

Malignant bone tumors are rare conditions that may be encountered by nononcologic surgeons only a few times in their careers, but a delay in diagnosis or a misinterpretation of data can have limb and life-threatening consequences. Prior literature suggests that unplanned resection of sarcoma was associated with an increased risk of local recurrence, decreased 10-year survival, and increased amputation rate compared with planned resection. In addition to patient morbidity, missed diagnoses and unplanned excisions of malignant tumors lead to increased cost of treatment and higher likelihood of subsequent medicolegal action. According to the American Cancer Society, the 5-year survival of all combined cases of malignant bone tumors is approximately 70%. However, the survival rate of each type of malignant bone tumor varies, with multiple myeloma survival rates being much lower and lymphoma somewhat higher. These rates depend on many factors including grade, stage, and chemotherapy response. For example, the 10-year survival of localized osteosarcoma is almost 70%, yet rapidly declines to 20 to 30% in patients with metastases. This further emphasizes the elevated importance of prompt recognition and treatment of malignant bone tumors.

show abstract

“…As mentioned, human LDH-A has been found overexpressed in various cancer tissues, including sarcomas [137,138]. Genetic silencing of LDH-A caused a reduced OS cell proliferation and migration in vitro, and in impaired tumorigenesis in vivo [139].…”

Section: Lactate and Sarcomasmentioning

confidence: 86%

Lactate in Sarcoma Microenvironment: Much More than just a Waste Product

Taddei

Pietrovito

Leo

et al. 2020

Cells

View full text Add to dashboard Cite

Sarcomas are rare and heterogeneous malignant tumors relatively resistant to radio- and chemotherapy. Sarcoma progression is deeply dependent on environmental conditions that sustain both cancer growth and invasive abilities. Sarcoma microenvironment is composed of different stromal cell types and extracellular proteins. In this context, cancer cells may cooperate or compete with stromal cells for metabolic nutrients to sustain their survival and to adapt to environmental changes. The strict interplay between stromal and sarcoma cells deeply affects the extracellular metabolic milieu, thus altering the behavior of both cancer cells and other non-tumor cells, including immune cells. Cancer cells are typically dependent on glucose fermentation for growth and lactate is one of the most heavily increased metabolites in the tumor bulk. Currently, lactate is no longer considered a waste product of the Warburg metabolism, but novel signaling molecules able to regulate the behavior of tumor cells, tumor-stroma interactions and the immune response. In this review, we illustrate the role of lactate in the strong acidity microenvironment of sarcoma. Really, in the biological context of sarcoma, where novel targeted therapies are needed to improve patient outcomes in combination with current therapies or as an alternative treatment, lactate targeting could be a promising approach to future clinical trials.

show abstract

Prognostic significance of serum lactate dehydrogenase levels in Ewing's sarcoma: A meta-analysis

Cited by 34 publications

References 32 publications

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Malignant Bone Tumors of the Knee: How to Identify and Treat

Lactate in Sarcoma Microenvironment: Much More than just a Waste Product

Contact Info

Product

Resources

About